NEW YORK, NY - MARCH 28: Traders work on the floor of the New York Stock Exchange on March 28, 2014 in New York City. The Dow Jones industrial avererage was up over 100 points in afternoon trading. (Photo by Spencer Platt/Getty Images)

Genetic Technologies trades as part of the medical diagnostics and research industry and trades as part of the healthcare sector. The company CEO is Paul A. Kasian. Genetic Technologies is a molecular diagnostics company which offers predictive testing and assessment tools to help physicians manage women’s health. It has developed BREVAGenplus, which is a is a clinically validated risk assessment test.

Previous Intraday Performance:

The GENE shares had a previous change of -3.51% which opened at 0.81 and closed at 0.81. It moved to an intraday high of 0.84 and a low of 0.80.

SeekingAlpha:  Biotechs up out the gate on Lilly/Loxo tie-up and start of JPM19

Historical Performance:

Over the last five trading days, GENE shares returned -11.82% and in the past 30 trading days it returned -2.56%. Over three months, it changed 35.04%. In one year it has changed -34.65% and within that year its 52-week high was 2.04 and its 52-week low was 0.51. GENE stock is 58.28% above its 52 Week Low.

Our calculations result in a 200 day moving average of 1.01 and a 50 day moving average of 0.84. Right now, GENE stock is trading -20.04% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  Biotechs up out the gate on Lilly/Loxo tie-up and start of JPM19


The company has a market cap of $14.3m with 17.6m shares outstanding and a float of 17.6m shares. Trading volume was 33,188 shares and has experienced an average volume of 49,396 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for Genetic Technologies was 0 which ended on 30th of June 2018.

Below was the last reported quarterly earnings per share:
06-30-2018:  0.00 (estimated)
06-30-2017:  0.00
06-30-2016:  0.00
06-30-2015:  0.00

The next earnings report will be: 03-27-2019

The long-term trend of the EPS is a vital number as it helps understand the future potential of Genetic Technologies.

Indicators Also to Watch:

Based on the latest filings, there is 4.30% of institutional ownership.

I calculated the beta to be 3.99

Business Wire:  CynergisTek, Inc. Sells Managed Print Services Business to Vereco, LLC for $30 Million

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -69.60%, return on assets is -58.31%, price-to-sales is 232.21 and price-to-book is 4.76.

Company Score Card:

Results are out of six:
 0  : Growth Expectations Result
 4  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here